TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway. TJ-M2010-5 inhibited MyD88 homodimerization in transfected HEK293 cells in a concentration-dependent manner and suppressed MyD88 signaling in LPS-responsive RAW 264.7 cells in vitro.
In a 10-week CAC mouse model (n = 30 per group), TJ-M2010-5 treatment statistically significantly reduced AOM/DSS-induced colitis and completely prevented CAC development with less related body mass loss, resulted in 0% mortality of treated mice (compared with 53% mortality of control mice), decreased cell proliferation, and increased apoptosis in colon tissue. TJ-M2010-5 treatment also inhibited production of inflammatory cytokines and chemokines (TNF-α, IL-6,G-CSF, MIP-1β, TGF-β1, IL-11, IL-17A, IL-22 and IL-23) and infiltration of immune cells (macrophages, dendritic cells, neutropihls and CD(+)4 T cells) in colon tissues of mice.
Cell Experiment | |
---|---|
Cell lines | RAW 264.7 cells |
Preparation method | RAW 264.7 cells were cultured in RPMI medium 1640. After stimulation with 100ng/mL of lipopolysaccharide (LPS) for six hours with 40 µM TJ-M2010-5 or vehicle one hour pretreatment, cells in individual wells were harvested for protein extraction. |
Concentrations | 40 µM |
Incubation time | 6 hours |
Animal Experiment | |
---|---|
Animal models | Female BalB/c mice (6–8 weeks old) |
Formulation | vehicle (ddH2 O) |
Dosages | 50mg/Kg daily |
Administration | i.p. |
Molecular Weight | 406.54 |
Formula | C23H26N4OS |
CAS Number | 1357471-57-8 |
Solubility (25°C) | DMSO 90 mg/mL |
Storage | 4°C, protect from light, sealed |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related Immunology/Inflammation Products |
---|
Evorpacept
Evorpacept (ALX148) is a high affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region designed to enhance the activity of other anti-neoplastic therapies, with minimal additional toxicity. |
Litifilimab
Litifilimab is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). |
Belatacept
Belatacept (BMS 224818) is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. Belatacept binds to CD 80/86 ligands and thereby inhibits the CD-28-mediated T-cell costimulation. Belatacept can be used in the research of Immunosuppression in organ transplants. |
MK-4830
MK-4830 is a novel, first-in-class human IgG4 monoclonal antibody targeting the myeloid-specific ILT4 (immunoglobulin-like transcript 4) receptor. MK-4830 catalyzes reprogramming of tumour-associated macrophages, relieving myelosuppression and enhancing T cell function. |
Lobenzarit
Lobenzarit is an immunomodulator, possesses anti-oxidative. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.